Navigation Links
Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
Date:2/25/2009

SEATTLE, Feb. 25 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced a work-force reduction of approximately 25 percent, or 25 employees, and a corporate restructuring. In the face of continuing uncertainty in the capital markets and the global economy, Trubion is proactively taking steps to reduce its costs and align its current resources with its strongest near-term opportunities while positioning the company for long-term sustainability and success.

Following the restructuring, Trubion will continue to invest in the development of its proprietary program, TRU-016, and the efficient and timely advancement of select preclinical assets that it believes will have the greatest opportunity for value creation.

The company will also continue to support the programs developed under its collaboration with Wyeth, including TRU-015, SBI-087 and other undisclosed product candidates. Trubion remains dedicated to its Wyeth partnership and will continue to allocate resources to support its clinical and research commitments under the collaboration.

In 2009, Trubion anticipates the following milestones for its proprietary and partnered product candidates:

-- Announce TRU-016 Phase 1 chronic lymphocytic leukemia dose escalation trial data by end of Q2 2009

-- Announce TRU-016 Phase 2a chronic lymphocytic leukemia expanded cohort trial data by end of Q4 2009

-- Disclose next investigational new drug candidate by end of Q2 2009 for application in 2010

-- Announce TRU-015 Phase 2b (15002) rheumatoid arthritis re-treatment data at the annual meetings of the European League Against Rheumatism and the American College of Rheumatology (ACR)

-- Announce TRU-015 Phase 2b (2203) rheumatoid arthritis trial data by end of Q
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Trubion Announces Presentations at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
3. Trubion Announces Presentations at Upcoming Investor Conferences
4. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Trubion Announces Presentations at April/May Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
10. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 AbilTo, Inc., the nation,s leading ... submission has been accepted as a presentation to be ... taking place on June 5-6, 2015 in Boston, ... American Diabetes Association, the cost of diabetes to the ... a result of increased inpatient, outpatient, and pharmacy costs, ...
(Date:4/21/2015)... DIEGO , April 21, 2015 ... design and development, custom automation, and contract manufacturing, ... and accessible flow cytometry and cell sorting technology ... to develop a novel flow cytometry platform. ... , NanoCellect Biomedical has developed a microchip-based cell ...
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... announced that its Board of Directors has elected ... of the Transaction and Pricing Committee, with oversight on ... a member of the Audit Committee, the Compensation Committee ... Upon his election, Mr. Azria commented: "I have a ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading provider ... Josh Forsythe as VP of Marketing. Mr. Forsythe ... a significant expansion in its commercial operations over the last ... " Josh Forsythe is a tremendous addition to ... MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing software ...
Breaking Biology Technology:AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... Phase 1 clinical studies support advancement to Phase 2 ... Roche polymerase inhibitors -, BRISBANE, Calif., Sept. 24 ... four abstracts from clinical and,in-vitro studies of ITMN-191 (R7227) ... American Association for the Study of Liver Diseases,(AASLD, Oct. ...
... new screening platform for antibody therapeutics, BASEL, ... today that it has completed the acquisition of ... of ARIUS Research (TSX: ARI). On,September 19th, the ... previously approved by the security holders and announced ...
... signing to follow his presentation, WASHINGTON, Sept. ... global marketplace, and the role of,financing are focus ... presentations will focus on the convergence of the,MedTech ... patient monitoring,technologies, critical issues to consider when entering ...
Cached Biology Technology:InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 2InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 3InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 4InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 5InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 6Roche completes acquisition of ARIUS 2Former Speaker of the House Newt Gingrich Featured Wednesday 2
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... upcoming paper from Dr. David Wassarman (University of Wisconsin ... 1 issue of G&D lends new insight into the ... (A-T) is a rare, genetic immunodeficiency disease that affects ... cancer predisposition. A-T is caused by recessive mutations in ...
... to designing something, its hard to find a better ... principle, a diverse, interdisciplinary group of researchers at the ... to synthesize magnetic nanoparticles that could be used for ... high-density memory devices, or as magnetic seals in motors. ...
... nature vs. nurture debate is familiar to most people, ... two. A new paper published this week in the ... similar balance between the genes we inherit—nature—and the environment—nurture—in ... the age of personal genomics, in which each of ...
Cached Biology News:Researchers mimic bacteria to produce magnetic nanoparticles 2Researchers mimic bacteria to produce magnetic nanoparticles 3
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
...
Recalibration of HL-2000-CAL products...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
Biology Products: